1. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, (eds). Kelley’s Textbook of Rheumatology. Sixth ed, Philadelphia. WB Saunders. 2001;921-66.
2. Dass S, Vital EM., Emery P. Rituximab. In: Rheumatoid Arthritis, Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME. Weisman MH (eds). Mosby.2009;362-366.
3. Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature;Salvarani;Autoimmun Rev,2019
4. Dörner T et al.: Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis;Buch;Ann Rheum Dis.,2011
5. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))